WMSA
VRDN icon

Weiss Multi-Strategy Advisers’s Viridian Therapeutics VRDN Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-125,000
Closed -$2.72M – 468
2023
Q4 		$2.72M Sell
125,000
-6,671
-5% -$105K 0.07% 330
2023
Q3 		$2.02M Sell
131,671
-24,580
-16% -$469K 0.05% 373
2023
Q2 		$3.72M Buy
156,251
+92,283
+144% +$2.37M 0.08% 352
2023
Q1 		$1.63M Buy
63,968
+3,968
+7% +$127K 0.04% 451
2022
Q4 		$1.75M Sell
60,000
-10,000
-14% -$230K 0.05% 403
2022
Q3 		$1.44M Buy
70,000
+44,961
+180% +$808K 0.04% 460
2022
Q2 		$290K Buy
+25,039
New +$337K 0.01% 589

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Weiss Multi-Strategy Advisers's VRDN Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Viridian Therapeutics (VRDN) in Q1 2024, closing a stake of 125,000 shares — an estimated $2.72M sold.

Weiss Multi-Strategy Advisers first reported a position in VRDN in Q2 2022 and held it in 7 quarters. The position peaked at $3.72M in Q2 2023. 136 funds tracked by Wall St. Rank hold VRDN as of Q1 2024.

  • Weiss Multi-Strategy Advisers reported no remaining Viridian Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 125,000 Viridian Therapeutics shares in Q1 2024, an estimated $2.72M.
  • Weiss Multi-Strategy Advisers first reported a position in Viridian Therapeutics in Q2 2022 and held it in 7 quarters.
  • Weiss Multi-Strategy Advisers's Viridian Therapeutics position peaked at $3.72M in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.